EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers

Dongxue Liu, Linlin Hu, Hua Shao iD

Cancer Chemotherapy and Pharmacology · 2023-09 · 92 (3) · 165-179

DOI: 10.1007/s00280-023-04541-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 06.07.2023. Verfasst von Dongxue Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Drug Monitoring, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, CHIA TAI TIAQING Pharmaceutical Foundation of Jiangsu Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a new means of oncology treatment, immune checkpoint inhibitors (ICIs) can improve survival rates in patients with resistant or refractory tumors. However, there are obvious inter-individual differences in the unsatisfactory response rate, drug resistance rate and the occurrence of immune-related adverse events (irAE). These questions have sparked interest in researchers looking for a way to screen sensitive populations and predict efficacy and safety. Therapeutic drug monitoring (TDM) is a way to ensure the safety and effectiveness of medication by measuring the concentration of drugs in body fluids and adjusting the medication regimen. It has the potential to be an adjunctive means of predicting the safety and efficacy of ICIs treatment. In this review, the author outlined the pharmacokinetic (PK) characteristics of ICIs in patients. The feasibility and limitations of TDM of ICIs were discussed by summarizing the relationships between the pharmacokinetic parameters and the efficacy, toxicity and biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringImmune Checkpoint InhibitorsHumansBiomarkersMedical Oncology

Stichwörter der Autor:innen

Immune checkpoint inhibitors (ICIs)Peripheral blood biomarkersPharmacokinetic propertiesTherapeutic drug monitoring (TDM)

Substanzen

Immune Checkpoint InhibitorsBiomarkers

Autor:innen und Institutionen

  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Office of Medication Clinical Institution, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Office of Medication Clinical Institution, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. gycsh@163.com.

ORCID-Profile: Hua Shao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • CHIA TAI TIAQING Pharmaceutical Foundation of Jiangsu Pharmaceutical Association

Zitieren

APA

Liu, D., Hu, L., & Shao, H. (2023). Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. Cancer Chemotherapy and Pharmacology, 92(3), 165-179. https://doi.org/10.1007/s00280-023-04541-8

Vancouver

Liu D, Hu L, Shao H. Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. Cancer Chemotherapy and Pharmacology. 2023;92(3):165-179. doi:10.1007/s00280-023-04541-8

BibTeX
@article{Liu2023,
  author = {Liu, Dongxue and Hu, Linlin and Shao, Hua},
  title = {Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  volume = {92},
  number = {3},
  pages = {165--179},
  doi = {10.1007/s00280-023-04541-8}
}
Kostenlos starten →